Drug Profile

CRMA 1001

Alternative Names: CRMA-1001

Latest Information Update: 03 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chroma Medicine
Developer nChroma Bio
Class Antivirals; Gene therapies
Mechanism of Action Gene silencing

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Hepatitis B
Preclinical Hepatitis D

Most Recent Events

28 Jan 2026 nChroma Bio receives CTA approval from the regulatory authority for CRMA 1001 in New Zealand and United Kingdom
28 Jan 2026 nChroma Bio plans a clinical trial for Hepatitis B in New Zealand and United Kingdom
22 Dec 2025 Phase-I/II clinical trials in Hepatitis B in Hong Kong, New Zealand (IV) (NCT07200193)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com